Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542382 · ClinicalTrials.gov registry record · Phase 1
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04542382 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 11 participants.
The verdict
NCT04542382, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).
Interventions
- DRUG Eltrombopag
- DRUG Rosuvastatin
- DRUG Rosuvastatin (Inhibitor arm)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542382
The ClinicalTrials.gov registry entry for NCT04542382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Eltrombopag is the first listed.
NCT04542382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542382 about?
NCT04542382 is a clinical study titled "Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)". This is an open-label, non-randomized, fixed-sequence study. Subjects will undergo a rosuvastatin phase and eltrombopag and rosuvastatin phase to identify biomarkers for Breast Cancer Resistance Protein (BCRP).
What is the current status of trial NCT04542382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2021-10-28. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT04542382?
The interventions under investigation include: Eltrombopag (DRUG), Rosuvastatin (DRUG), Rosuvastatin (Inhibitor arm) (DRUG).
Who is sponsoring clinical trial NCT04542382?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.